Overview

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Status:
Recruiting

Trial end date:
2027-10-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the results of treating patients with HPV-unrelated head and neck squamous cell carcinoma with neoadjuvant single-agent palbociclib, followed by chemoradiation (either cisplatin + IMRT or cetuximab + IMRT depending on patient characteristics), followed by adjuvant single-agent palbociclib.

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Collaborator:

Pfizer

Treatments:

Cetuximab
Cisplatin
Palbociclib